Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
Metastatic or recurrent tumors are the primary cause of cancer-related death. For prostate cancer, patients diagnosed with local disease have a 99% 5-year survival rate; however, this 5-year survival rate drops to 28% in patients with metastatic disease. This dramatic decline in survival has driven...
Saved in:
| Main Authors: | Koran S. Harris, Bethany A. Kerr |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2017/8629234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anoikis in prostate cancer bone metastasis gene signatures and therapeutic implications
by: Wei Xia, et al.
Published: (2024-09-01) -
Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?
by: Bertrand Tombal, et al.
Published: (2012-01-01) -
Biochemical markers of bone metastasis
by: N. V. Lyubimova, et al.
Published: (2015-06-01) -
A case of rapidly progressive prostate cancer with bone and lymph node metastasis after contact laser vaporization for benign prostatic hyperplasia
by: Kei Muraoka, et al.
Published: (2025-01-01) -
FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system
by: Xiaolong Liu, et al.
Published: (2025-03-01)